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Background: A mother’s own milk (MOM) is the gold standard for the feeding and
nutrition of preterm and full term infants. When MOM is not available or there is
not enough, donor human milk (DHM) should be used. Milk delivered to Human
Milk Banks (HMBs) should be pasteurized to inactivate viral and bacterial agents.
Currently, a pasteurization process at 62.5◦C for 30min (Holder pasteurization, HoP)
is recommended in all international HMBs guidelines.
State of the art: It is known that HoP affects some of the nutritional and biological
components of human milk. Studies have demonstrated that temperature cycle in
HoP is not always controlled or calibrated. A better check of these parameters in the
pasteurizers on the market today may contribute to an improvement of the quality of HM,
still maintaining some of the negative effects of the heat treatment of human milk. So,
food industry, and dairy industry in particular, are evaluating innovative methodologies
alternative to HoP to better preserve the nutritional and biological properties of
fresh human milk, while assuring at least the same microbiological safety of HoP.
The most studied processing techniques include High-Temperature-Short-Time (HTST)
pasteurization, High Pressure Processing (HPP), and Ultraviolet-C (UV-C) irradiation.
HTST is a thermal process in which milk is forced between plates or pipes that are heated
on the outside by hot water at a temperature of 72◦C for 5–15 s. HPP is a non-thermal
processing method that can be applied to solid and liquid foods. This technology
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inactivates pathogenic microorganisms by applying a high hydrostatic pressure (usually
300–800 MPa) during short-term treatments (<5–10min). UV irradiation utilizes short-
wavelength ultraviolet radiation in the UV-C region (200–280 nm), which is harmful to
microorganisms. It is effective in destroying the nucleic acids in these organisms, so that
their DNA is disrupted by UV radiation.
Aim: The aim of this paper is to present the EMBA recommendations on processing of
HM, based on the most recent results obtained with these new technologies.
Conclusions: Although research on the most promising technologies that will represent
an alternative to HoP (HTST, HPP, UV-C) in the future is progressing, it is now important
to recognize that the consistency and quality assurance of the pasteurizers on the
market today represent a fundamental component that was previously lacking in the
Holder approach.
Keywords: processing of human milk, donor human milk, human milk, human milk bank, preterm infants, infant
nutrition
BACKGROUND
The increasing number of infants who are born extremely
preterm and survive at birth and beyond, with a gestational
age as low as 22 weeks, represents a new challenge for
neonatal nutrition. In the last few decades, human milk
(HM) has been identified as the normative standard for
premature infant feeding and nutrition by health organizations
and scientific societies (1–3). HM confers to these infants
protection against necrotizing enterocolitis, sepsis and other
infections, and severe retinopathy, decreases the risk of death,
and improves their long-term neurocognitive development
and cardiovascular health. In addition, the benefits of breast-
feeding to promote psychological health and mother-infant
bonding are well-known. A mother’s own milk (MOM) is
the first choice for premature infant feeding. When there
is not sufficient MOM (a common occurrence in Neonatal
Intensive care Units), donor human milk (DHM) obtained
from well-established human milk banks (HMBs) is the
best alternative. The WHO/UNICEF Joint Statement clearly
indicates: “HMBs should be made available in appropriate
situations” (4).
DHM delivered to HMBs should be pasteurized to inactivate
viral and bacteriological agents (5). The ideal pasteurization
process should consist of a rapid heating phase, followed by
a phase in which the temperature is maintained constant, and
a final rapid cooling phase. Currently, a pasteurization process
performed at a temperature of 62.5◦C for 30min, which is known
as the Holder pasteurization (HoP) method, is recommended
in all international guidelines for the establishment and
management of HMBs (5, 6). Pasteurized HM is known to
retain many beneficial and protective components of fresh
HM (5). However, it also affects some of the nutritional
and biological properties of HM and eliminates the beneficial
microbiota of fresh HM, thus resulting in the reduction of some
bacteriostatic mechanisms that render milk more susceptible
to postheating bacterial contamination, and decreases in its
nutritional value (5).
Due to the present limitations of HoP in processing of HM,
there is the need to evaluate alternative processing methods
able to preserve better the bioactivity of a higher number
of HM components in order to improve the nutritional and
immunological quality of DHM.
New technologies are under study and the purpose of this
manuscript is to evaluate the results obtained from the most
promising ones.
STATE OF THE ART AND FUTURE TRENDS
HM is a functional and dynamic biologic system: it provides
nutrients, bioactive components and immune factors, and it
promotes an adequate and healthy growth of newborn infants.
Milk delivered to HMBs should be pasteurized to inactivate viral
and bacterial agents, as well as a mother’s own milk in specific
clinical situations.
Currently, HoP is the most frequently studied and
recommended method for the heat treatment of donor
HM (5–8). A recent review has shown a significant variability in
the data reported in scientific literature concerning the effects
of HoP on the biological components of HM (9). Possible
explanations for this variability could be the heterogeneity of the
test protocols applied in the studies, the fact that HoP is often
simulated in laboratories on small aliquots of milk rather than
being performed with commercial instruments on the larger
volumes of milk utilized inside the HMBs, and, last but not least,
modern pasteurizers require significantly less time for heating
and cooling than older ones, thus changing the kinetics of the
thermal response for heat-sensitive compounds (9–12).
The loss of some biologically active components as a result
of HoP, including immunological components, is the main limit
to the spread of donor HM utilization in the feeding of preterm
infants (10, 11).
The optimization of the biological and nutritional quality of
DHM is considered, by the European Association of HumanMilk
Banks (EMBA), as a scientific and social priority. In order to
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investigate this aspect, the EMBA Board of Directors set up a
Working Group (WG), that is, a dynamic network of scientists
who perform research in the field of HMBs and HM treatment,
and who operate in different European countries. This WG
is aimed to evaluate old and new methodologies in order to
determine their effects on the final quality of DHM delivered
from HMBs. The objective is to obtain optimum levels of quality
and safety of DHM from milk banks in Europe and to decrease
the variability of HM, at least as far as the aspects related to
the effects of heat treatment are concerned. Quality has been
discerned as a powerful tool for the improvement of the well-
being of premature infants. A better management of DHM in
HMBs will improve the services for donor women (those who
donate milk) and for the recipients (the newborn infants who
receive it).
The main technologies taken into considerations by this
WG are the following: low-temperature long-time pasteurization
(LTLT), which has been evaluated by a French group in Lyon (RB
and JCP); high-temperature short-time pasteurization (HTST),
evaluated by two Italian groups located in Turin and Milan (EB,
LC, DL, and GEM); high pressure processing (HPP), evaluated by
a French group located in Bordeaux (CB and GD) and a Polish
group located inWarsaw (AW); and ultraviolet (UV) irradiation,
performed by the Spanish group located in Palma deMallorca (JC
and AG).
Low-Temperature Long Time
Pasteurization
At present, the most common practice utilized for the treatment
of DHM is a low-temperature (62.5◦C) long-time (30min)
pasteurization (LTLT), which is known as Holder pasteurization
(HoP). HoP is recommended in all the international guidelines.
Milk pasteurization with HoP is known to retain many of the
beneficial and protective effects of HM, such as a reduction
in NEC and sepsis, protection against bronchopulmonary
dysplasia, and a lower rate of long-term complications, such as
cardiovascular diseases and neurodevelopmental disabilities (3).
However, some significant concerns have arisen, related to the
possible alterations of the nutritional and biological properties
of DHM, as a result of the heat treatment. HoP produces a loss
in the quantity and/or activity of some biologically functional
milk components to varying degrees (9). Other nutritional
and biological components, such as oligosaccharides, lactose,
glucose, LCPUFAs, gangliosides, vitamins A, D, E, and B12,
folic acid, some cytokines, and some growth factors are instead
preserved (9).
Different devices have been produced to perform LTLT
pasteurization. The most common heat source for pasteurization
is hot water, but moving hot air has also been used in some other
devices. In 2017, Buffin et al. showed that air pasteurizers have a
very different pasteurization pattern fromwater pasteurizers (12).
When the temperature recorded in the different bottles inside at
pasteurizer’s bath was measured, it was not homogenous, with a
difference of 21.7min between the first probe and the last probe
reaching 62.5◦C. Moreover, the plateau duration was on average
10min longer in air pasteurizers than in water pasteurizers.
Therefore, the exposure to temperature seems to be more
prolonged in the former devices (12). In fact, air is a less effective
thermal conductor than water. Its propulsion is uneven and leads
to temperature inhomogeneity in pasteurizer. This phenomenon
leads to the bottles undergoing a different treatment from each
other, and it is difficult to provide adjustments to improve
the process.
Water is the most homogeneous environment heat
conducting source, and it is therefore the most widely used
medium for HoP. Different devices exist on the market today,
but not all of them are provided with a temperature control
system. The duration of the heat treatment and the maximum
temperature of milk exposure have been shown to be essential
for the preservation of human milk. Evans et al. already
showed, back in 1978, that the alteration of the immunological
components of human milk began at a temperature of 60◦C and
became more significant at 65◦C (13). This was later confirmed
by Czank et al. who demonstrated a significant impact of the
temperature and an early alteration starting at 58◦C (14).
The study also demonstrated the influence of the duration of
pasteurization, with a loss of 1.6, 1.7, and 2.4%, respectively,
for IgA, lysozyme and lactoferrin per each minute spent at a
temperature of 62.5◦C (14).
The recording of the temperature of milk in several bottles,
by means of external probes, during the pasteurization cycle
showed significant differences, in terms of temperature or
the duration of exposure of HM, depending on the device.
The increase in the temperature of milk is in fact fast up
to 58◦C, but the inertia of heating is then responsible for
a slowing down of the rise in temperature up to 62.5◦C. It
has been demonstrated that HM immune components start to
be damaged significantly from 58◦C (14). The regulation of
each pasteurizer is therefore crucial to minimize the exposure
time responsible for the damage to HM. Buffin et al. reported
that the difference in exposure above 58◦C could be as much
as 10min longer, depending on the device. In addition, the
average temperature of the plateau can vary by nearly 0.8◦C.
These effects are only visible when several calibrated probes
are used (12, 15). It is important to note that the milk was
shaken during the heat treatment in both types of tested
pasteurizers (12).
A single recording probe in just one of the bottles does not
allow either the whole pasteurizing process to be understood
or deviances in the system to be detected. Since HoP is
currently conducted at a relatively high temperature (62.5◦C),
it is important to control this temperature and the duration
of exposure (12, 15). Furthermore, most of the studies that
have evaluated or compared HoP with other techniques have
not described the pasteurizer cycle precisely. The differences
that exist between pasteurizers can be important and can have
an important impact on the assessed components. This could
explain the discrepancies that have been found between the
different results in literature. These inconsistencies make it
difficult to make a definitive statement on the effects of HoP.
For these reasons, any future study on HoP should adopt a
standardized approach to ensure consistency. However, it is
important to recognize that where research on HoP is being
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carried out, consistency, and quality assurance adds a necessary
component that was previously lacking in the approach.
Therefore, a routine recording of the milk temperature in
one bottle located in the middle of a bath is important to
control each pasteurization cycle. This probe is not present
in all the pasteurizers available on the market today, and is
present even less in a simple water bath. Each pasteurizer
should be made to undergo regular quality controls, performed
by each HMB using several external probes. Some criteria
have recently been proposed (Table 1) (12, 15). Since 2016,
such quality controls have been performed regularly, at least
once a year, in the 36 French HMBs. Manufacturers should
provide these criteria when they propose qualified pasteurizers
to HMBs.
This qualification has two purposes:
• The first is to highlight a dysregulation of the pasteurizer;
• The second, which is based on the results, is to require the
manufacturer to adjust and optimize the regulation of the
pasteurizer in order to minimize the temperature plateau
range, the duration of the pasteurization plateau, and to ensure
cycle accuracy and repeatability.
Moreover, since HoP is the most frequently used technique, it
should be considered, as part of the optimization, whether a value
of 62.5◦C is the best temperature for the treatment of human
milk. Czank et al. have shown the effectiveness of pasteurization
on bacteria at temperatures above 57◦C. However, it is known
that Cytomegalovirus persists at this temperature, but it could be
useful to test intermediate temperatures, such as 60◦C and / or
shorter exposure times (14).
Finally, it should be kept inmind that the heating phase should
be followed immediately by a rapid chilling phase to 4◦C to
minimize the additional time during which the milk is exposed
to the high water bath temperatures and to reduce the further
destruction of heat labile components. This thermic shock could
also prevent aerobic spore-forming bacteria from multiplying.
As long as HoP remains the main technique utilized in HMBs,
it should be made as optimal as possible, with quality assurance
being obtained through checks and calibration.When comparing
HoP with new techniques, it should be ascertained that HoP
is performed correctly, and the comparison should be made in
TABLE 1 | Criteria for qualification of human milk pasteurizers (12, 14, 15).
• Measurement by calibrated temperature probes Independent of the
pasteurizer
• Regular distribution of the probes inside the pasteurizer
• One probe for 8–10 bottles
• Qualification repeated once a year and after major intervention, and
performed on three pasteurization cycles
• Temperature of the plateau as close as possible to 62.5◦C and below
64◦C
• Duration of the plateau as close as possible to 30min and <35min (time
calculated when all probes have reached 62.5◦C)
• Exposition time over 58◦C <50min for each probe
• Exposition time from 62.5 to 6◦C ≤ 1 h
conditions as close as possible to the routine daily practices in
the HMBs.
High-Temperature Short-Time (HTST)
Pasteurization
HTST was the first non-HoP technique tested to improve the
nutritional and immunological quality of milk, and it was first
established in the dairy industry in the 1930s (16). HTST is
usually performed by heating thin layers of milk in continuous
flow systems at 72◦C for 15 s. This technology has been
applied to the treatment of DHM with promising results (9).
Immunological components, and in particular immunoglobulins
(Igs), are known to be affected by HoP (17–19), and have often
been targeted as qualitative/functional parameters in studies on
alternative HM pasteurization technologies. Goldsmith et al.
were the first to test HTST pasteurization on HM using a
stainless steel laboratory capillary heat exchanger (20). They
reported comparable degradation after HTST and HoP for Igs
and lactoferrin. The retention of HM Igs was found to decrease
as the temperature and holding time increased. Therefore, the
search for an optimal compromise between microbiological
safety and biological quality should be made considering the
pasteurization equipment and the working conditions. Data
regarding the effect of HTST pasteurization on lactoferrin and
lysozyme concentrations and activities are sometimes divergent,
due to the fact that different methods were used to apply the
HTST technology in the different studies.
Overall, it has emerged that HTST performed at a laboratory
scale or pilot scale is at least equivalent to HoP in ensuring
HM microbiological safety, but is better at preserving the HM
antioxidant potential, lactoferrin content and structure, B and C
vitamins, and some cytokines.
Two HTST pasteurizers have recently been specifically
designed and validated for human milk processing (21, 22).
In the first study, a new small-scale, continuous-flow, HTST
pasteurizer was designed to treat HM. The efficacy of the new
HTST device was assessed on inoculated Listeria monocytogenes,
Staphylococcus aurous, and Chronobacter sakazakii, as well as
on raw human milk bacteria. The biological quality of the milk
was assessed after HTST pasteurization and compared with a
standard HoP, by determining the secretory IgA (sIgA) content,
the protein profile, lysozyme and the Bile Salt Stimulated Lipase
(BSSL) activities. No pathogen or bacterial growth was detected
after HTST pasteurization with the new instrument. Changes
in the protein profile were observed in the milk pasteurized
with both processes. The sIgA content and BSSL activity were
significantly higher in the milk pasteurized with the new device
than in the same milk treated with the standard HoP. In
conclusion, the new HTST apparatus was able to effectively
pasteurize HM and showed a better retention of the sIgA content
and a better BSSL activity (21). However, these results still have
to be confirmed in HMB conditions.
Escuder-Vieco et al. described HTST equipment designed
specifically for the continuous and adaptable (time-temperature
combination) processing of DHM, considering the specific needs
of a human milk bank (22). Microbiological quality, the activity
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of the indicator enzymes and indices for thermal damage to
HM were evaluated before and after HTST treatment using
different temperature and time combinations and the results
were compared with the results obtained after HoP (22). The
HTST system had an accurate and simple operation mechanism,
which allowed the pasteurization of variable amounts of DHM
and reduced both the processing time and the labor force.
HTST processing at 72◦, for at least 10 s, effectively destroyed
all the vegetative forms of the microorganisms that were initially
present in the raw DHM. Alkaline phosphatase was completely
destroyed after HTST processing at 72 and 75◦, but γ-glutamil
transpeptidase showed higher thermoresistance, thus indicating
that this could be used as a quick, simple, and inexpensive test.
The furosine concentrations in HTST-treated donor HM were
lower than those obtained after HoP, and the lactulose content
for HTST-treated DHM was below the detection limit of the
analytical method (10 mg/L). The absence of lactulose and the
small amount of furosine found in HTST-treated DHM indicated
that a heat treatment with this new HTST equipment did not
induce any significant heat damage to DHM. In addition, a higher
retention of immunoglobulins, some hormones, BSSL activity
and antioxidant capacity were found in HTST-treated DHM
samples than in the samples treated by means of HoP (22).
High Pressure Processing (HPP)
HPP is a well-known technique in the food industry, and it is
considered a promising alternative to the thermal pasteurization
of HM. HPP is a non-thermal processing method that can be
applied to solid and liquid foods to provide microbiologically
safe, nutritionally intact, and sensory high-quality products
(23). This technique inactivates pathogenic microorganisms
by applying high hydrostatic pressure (usually 400–800 MPa)
through short-term treatments (<5–10min) (24).
Viazis et al. were the first to point out the retention of
nutrients and the bioactivity and microbial safety of pascalized
HM (25, 26).
Other researchers have shown that HM activity after processed
over a 300 to 650 MPa HPP range is similar to heat-treated
milk. IgA, IgM, IgG, lysozyme, lactoferrin, cytokines (EGF, TGF-
β1 and TGF-β2, IL-6, IL-8, TNF-α, IL-12, IL-17, and IFN-γ) α-
and δ-tocopherol, and free nucleotidemonophosphates are partly
preserved (27–32).
The destruction of Listeria monocytogenes, Eschericha coli,
Staphylococcus aurous, and Salmonella spp, within the 300–400
MPa pressure range, is comparable with the microbiological
purity obtained after thermal pasteurization (25, 28, 33).
Moreover, recently obtained results suggest that anHPP
treatment, at pressures below 600 MPa for 15min, allows the
antirotaviral activity to be retained (34).
This technique respects the sensorial and nutritional
properties of food better than HoP, because of the absence of a
heat treatment (35, 36). As far as the safety and taste satisfaction
of donor milk recipients are concerned, the profile of the
volatile milk components has been examined after processing.
Generally, the change in the sensory quality of human milk after
a high-pressure treatment has been found to be less than that
caused by HoP (35, 36).
It should be taken into consideration that a change in the
lipid fraction may take place as a result of HPP. Milk fat
is distributed as globules in colloidal fluid produced by the
mammary gland. Any physical factor that is able to influence the
stabilization of this component, either pressurization or a warm
temperature, causes a decreased fat globule size, which is defined
as a homogenization (37).
Exposure to pressures below 600 MPa has not been found
to influence the content or composition of the lipid fraction of
HM. However, increasing pressure above this limit might result
in undesirable changes in the content of selected fatty acids in
human milk. A risk of lipid oxidation products in HM after
processing has been reported (38, 39).
The HPP technique seems to offer clear advantages over
HoP: it results in an improved nutritional quality product; it
is faster and perhaps more convenient than HoP; it can be
applied to frozen milk samples and it can be used on samples of
variable size.
A French team from Bordeaux and a Polish team from
Warsaw, with representatives from the EMBA Working Group
(CB and AW), have evaluated this technology with positive
results. HPP seems to be able to better maintain some milk
proteins (HGF, lactoferrin, IgG), and to preserve active hormones
(leptine, adiponectine, insulin, erythropoietin) and enzymes
(lipase) (EMBA International Conference on Donor Human
Milk, Glasgow, October 5–6th, 2017). Until recently, it was
considered that vegetative cells are more effectively destroyed
by HPP than endosporic forms. Billaud and Demazeau have
recently optimized the operational parameters (pressure, rate,
decompression, and application mode) and this has allowed the
inactivation of B. cereus spores. Under these conditions, the
activity of certain important human milk biological components,
such as lipase activity and immune proteins, is maintained. These
results were obtained with a pressure of 350 MPa (40).
Themain obstacle to the use of HPP in humanmilk treatment,
is the scaling down of the equipment and the investment and
operating costs. It has been calculated on the basis of a cost
consequence analysis conducted with a regional model of human
milk banking operating in Poland, that the cost of pascalized
donor milk will be 130% higher than milk treated by means of
Holder (unpublished data). However, there are some small and
medium-size enterprises in Poland that are interested in investing
in the human milk bank market. The prototype equipment for
human milk pascalization has already been described, and the
next step will be to obtain the money to construct and validate
the device (Figure 1).
At present, only prototypes of these HPP devices exist, and
this technique still has to be tested under HMB conditions.
Ultraviolet-C Irradiation
Ultraviolet (UV) irradiation utilizes short-wavelength ultraviolet
radiation in the UV-C region (200–280 nm), which is harmful
to microorganisms. It is effective in destroying the nucleic acids
in these organisms, so that their DNA is disrupted by the UV
radiation, leaving them unable to perform vital cellular functions.
The greater the exposure to UV rays, the better the result, and this
ensures a complete destruction of all the microorganisms (1, 3).
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FIGURE 1 | Prototype and parameters utilized for high pressure processing of human milk.
UV light only penetrates food materials by several millimeters,
depending on the optical properties of the product. Ultraviolet
light penetrates the cells, but does not alter the food that is being
treated. The color and/or turbidity of the liquid influences its
optical absorption coefficient. UV light cannot penetrate milk or
other cloudy foods, like other opaque foods. As a consequence,
these substances must be presented to the system as a thin layer,
and this constitutes a concern when large volumes of donor HM
in HMBs are being treated daily (41, 42).
Some preliminary reports have shown that UV irradiation is
able to produce a reduction of 5 log 10 in the exogenously-added
bacteria in HM, without affecting the lipase activity (43). The
concentrations of lactoferrin, lysozyme and immunoglobulin A
(IgA) have been described as basically being unaltered (44), and
it has also recently been reported that ultraviolet -C radiation
is able to inactivate cytomegalovirus in HM under the correct
conditions (45).
The main challenge to testing this methodology is the lack of
appropriate equipment in the humanmilk bank context. In order
to further analyze the potential application of UV-C irradiation
in this context, a Spanish group from Palma de Mallorca (JC and
AG), has designed an instrument in whichmilk is kept in motion,
through the use of a magnetic stirrer bar, which creates a low
velocity, laminar flow vortex, thus transporting and overcoming
the low penetrance of UV irradiation. Figure 2 demonstrates
the instrument, which allows 500ml of milk to be processed: it
consists of a graduated cylinder glass tube in which a 26 cm long
UV-C lamp with 8w power has been introduced, so that 10min
of treatment equals 9,600 Joules/Liter (LIT-06; Instrumentación
Científico Técnica S.L., La Rioja, Spain). In this treatment, the
milk is kept at room temperature and agitated with a magnetic
bar and a stirrer at 200 rpm.
With this device, Calvo and Gaya tested five different 500ml
batches of DHM that had been discarded during routine
FIGURE 2 | Schematic representation of the device used to treat donor
human milk with UV-irradiation.
processing in their HMB due to the presence of high levels of
contamination. Of the five analyzed samples, two presented>105
CFU/ml and three >106 CFU/ml. In all cases, the contamination
was due to a mixed flora, including gram-negative bacteria. A
sample was taken at different times after the treatment was
started (0, 15, 30, 45, and 60min) and the number of CFU was
quantified by means of conventional microbiological techniques.
These experiments showed that, after 30min of treatment, the
amount of CFU/ml was reduced by five orders of magnitude
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(log10) in all cases. The fact that the used samples were
representative of the DHM samples usually treated in a HMB is of
particular relevance.
Bacillus is a bacteria genus that is frequently found in DHM,
and it represents a special concern for HMBs, as these bacteria
are capable of producing heat-resistant toxins and forming spores
that are resistant to pasteurization (46, 47). In the HMB of Palma
de Mallorca, about 10% of the milk is generally discarded due
to the presence of Bacillus sp. In order to test the susceptibility
of Bacillus sp to the UV treatment, the researchers used two
different batches of donormilk that had been discarded as a result
of contamination with Bacillus sp., 3,000 CFU/ml in both cases.
The results showed that after 45min of treatment, the Bacillus sp.
were eliminated.
The Spanish group then evaluated the effect on the biological
components of HM. One of the main biological components is
IgA, which constitutes 90% of all the immunoglobulins present
in colostrum and HM. Its importance lies not only in its
concentration, but also in its biological activity (48). It has been
pointed out that pasteurization affects IgA levels to different
extents, depending on the pasteurization temperature (14). In the
case of HoP, a clear decrease in IgA concentration was observed,
although there were large discrepancies in the range of reduction,
from 20 to 60% (9). The results of this group have shown that,
after testing seven different batches of DHM, the IgA levels
measured by conventional nephelometry techniques, were 96%
of the pre-treatment levels, and in five samples, a 100% activity
was preserved.
From these results, it can be concluded that the treatment
with UV-C light has a number of features that make it a good
candidate as an alternative to HoP. In addition to providing
a better protection of the biological components than other
methods, it is also capable of producing an at least 5-log10
decrease in the number of bacteria (including Bacillus sp)
present in DHM. Furthermore, the ability of UV-C radiation to
eliminate active forms of Cytomegalovirus in HM has also been
demonstrated (45). Unfortunately, until now, there is neither a
device nor even a prototype that would enable the use of this
technology in an HMB setting.
EMBA Working Group Recommendations
One important aspect that should be considered when evaluating
the processing of humanmilk is the viral inactivation effect of the
new methodologies.
The ability of LTLT pasteurization to inactivate viral
pathogens is well-known. The list of human viruses inactivated
by HoP includes pathogens for which transmission through
breastfeeding has been conclusively demonstrated (i.e., the
human immunodeficiency virus, human T-cell lymphotrofic
virus, cytomegalovirus), and viruses that can be transmitted via
breast milk, such as human papillomavirus, Zikavirus, Ebola and
the Marbourg virus (49–55).
On the other hand, virus inactivation still has to be carefully
evaluated for each alternative technique and device designed to
treat breast milk. This is an important issue for future research.
We can state that fundamental knowledge of new technologies
of HM processing is still lacking. Their effects on safety and
bioactive components of HM need further evaluation. Table 2
presents the “state of the art” at the moment, explaining
advantages, and disadvantages of the processing techniques
described in this paper.
On the basis of evidence taken from the literature and
on the personal experience of its members, the Working
Group on the Processing of Human Milk makes the
following recommendations:
When testing new technologies, the following requirements
should be fulfilled:
- The equipment should be described precisely
- The control of the equipment and repeatability of the process
should be demonstrated
- The process parameters should be recorded
- Tests should not be performed only at a lab scale, but also in
an HMB environment
The final aim ofHMprocessing performedwith new technologies
should be:
- To improve the preservation of the nutritional and bioactive
components of raw HM (in order to at least ensure the same
microbiological safety as HoP)
- To improve the microbiological safety of treated DHM, taking
into account the inactivation of spores, even though this aspect
is not at present considered in all the guidelines that regulate
the activity of HMBs
- To inactivate the viral effect on human viruses for which
transmission through breastfeeding has been demonstrated
FIGURE 3 | Workflow for assessing the performance of new pasteurization
technologies for human milk. *For the qualification of the Holder pasteurizer,
see Buffin et al. (12).
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TABLE 2 | Advantages and disadvantages of the processing techniques described in this paper.
Processing Technique Advantages Disadvantages
Low-Temperature Long-Time
Pasteurization (LTLT), known as
Holder Pasteurization (HoP)
- Best known methodology
- Recommended in all international guidelines for the
constitution of Human Milk Banks
- Well-established antimicrobial and antiviral activity
- Retention of many beneficial and protective effects of
human milk
- Reduction/disruption of important nutritional and
immunological factors of human milk
- Ineffective against bacterial spores (Bacillus cereus)
- Need of regular requalification of the pasteurizer
High-Temperature Short-Time
Pasteurization (HTST Pasteurization)
- Utilized in dairy industry since 1930s
- Less thermal stress (processing time in seconds and not in
minutes)
- Better retention of sIgA and lipase activity in comparison to
HoP
- Smaller loss in antioxidant potential than HoP
- Prototypes have been used for comparative studies
- No device available on the market today
- Ineffective against bacterial spores (Bacillus cereus)
High Pressure Processing (HPP) - No thermal stress (processing at low temperature)
- Better retention of some important biological components
(lipase, lysozyme, lactoferrin, IgA) in comparison to HoP
- Inactivation of bacterial spores
- Higher microbial safety
- Antiviral activity needs a more deep evaluation
- Investment and operating costs are significantly higher than
a conventional pasteurizer
- Scaling down of the equipment represents a practical
problem
- Dimensions and weight of the apparatus make difficult the
placing in human milk banks
Ultraviolet-C irradiation (UV irradiation) - Emerging food preservation technique that retains higher
quantities of bioactive components
- Better retention of IgA in comparison to HoP
- Effective on elimination of Bacillus cereus spores
- Application of UV-C technology is difficult in human milk
- Only few preliminary reports are available
- Antiviral activity has to be evaluated
- Lack of appropriate equipment in a human milk bank setting
TABLE 3 | Parameters to evaluate for validation of new pasteurization technologies.
BIOCHEMICAL QUALITY
Parameter Unit Method
sIgA ng/ml Giribaldi et al. (21)
BSSL activity µmol/min/ml Giribaldi et al. (21)
Lysozyme activity U/µl Giribaldi et al. (21)
MICROBIOLOGICAL QUALITY§
Inoculated bacteria Initial loads in raw milk (CFU/mL) Final loads in pasteurized milk (CFU/ml) Method
Listeria monocytogenes 1.2 × 106 Absent in 25ml EN/ISO 11290, 1996 (21)◦
Staphylococcus aureus 3.0 × 106 <100 EN/ISO 6888, 1999 (21)◦
Chronobacter sakazakii 1.6 × 106 Absent in 10ml AFNOR V08-054, 2009 (21)◦
CMV Absent Hamprecht et al. (51)◦
HIV Absent Giribaldi et al. (21)◦
§ For the design of the microbiological challenge test, see Giribaldi et al. (21).
◦ Or equivalent methods.
- Easy placement of the new plant in HMBs
- Low cost, in order to overcome the problem of the limited
financial resources of the majority of HMBs.
A workflow that can be considered suitable to assess the
basic performance of new pasteurization technologies
for HM is shown in Figure 3 and Table 3. Since Holder
pasteurization is not efficient in eradicating spore-forming
bacteria, this parameter has not been included in the validation
targets. However, any new pasteurization system that could
prove to be efficient against spore-forming bacteria (while
maintaining all the other aforementioned characteristics)
would represent a great advantage for the improvement of
HM safety.
CONCLUSIONS
This paper presents the recommendations of the EMBAWorking
Group on the “Processing of HM.” Although research on the
most promising technologies, which will represent a reasonable
alternative to HoP in the future (HTST, HPP, UV-C) is
progressing, at the moment it is important to recognize that the
consistency and quality assurance of the pasteurizers currently
available on the market today represent a fundamental approach
that was previously lacking in HoP practice.
EMBA recognizes that HoP is at present the safest
compromise for the treatment of DHM; however, further studies
are needed to improve this technology in order to minimize
its effects on the biological components of HM. The new
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technologies evaluated and studied by the Working Group are
being developed rapidly, and EMBA recommends that the final
aim of these technologies should be an improved preservation
of the nutritional and bioactive components of raw human milk,
while assuring microbiological safety of the product, at least at
the same level as optimized HoP.
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